In 2011, National Institute on Aging and Alzheimer's Association joint task forces released proposed criteria for Alzheimer' disease diagnosis. These proposals included revisions to the nearly 30-year-old NINDS-ADRDA criteria for Alzheimer's diagnosis and added criteria for diagnosis of Mild Cognitive Impairment (MCI) due to Alzheimer's disease. The same year the American Psychiatric Association proposed new criteria for major and minor neurocognitive disorders (the entities previously known as dementia and mild cognitive impairment, respectively). These new criteria reflect the research and…mehr
In 2011, National Institute on Aging and Alzheimer's Association joint task forces released proposed criteria for Alzheimer' disease diagnosis. These proposals included revisions to the nearly 30-year-old NINDS-ADRDA criteria for Alzheimer's diagnosis and added criteria for diagnosis of Mild Cognitive Impairment (MCI) due to Alzheimer's disease. The same year the American Psychiatric Association proposed new criteria for major and minor neurocognitive disorders (the entities previously known as dementia and mild cognitive impairment, respectively). These new criteria reflect the research and clinical advances in identifying mild cognitive impairment and offer new opportunities for prevention, treatment, and management of neurodegenerative conditions.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Dr. Glenn Smith is a board-certified clinical neuropsychologist and professor of psychology at Mayo Clinic In Rochester MN. He has served as principal investigator of the Mayo Alzheimer's Disease Research Center Education Core. Dr. Smith has had continuous research funding since 1994 and has authored or co-authored over 180 original article on normal aging, mild cognitive impairment and dementia. He led development and directs Mayo's Dementia Behavior Assessment and Response Team (DBART) and HABIT (Healthy Action to Benefit Independence and Thinking) program for persons with Mild Cognitive Impairment. He is past president of the American Board of Clinical Neuropsychology and of the Division of Clinical Neuropsychology of the American Psychological Association. In addition to supervising postdoctoral fellows, he maintains an active diagnostic neuropsychology practice. Mark W. Bondi is a board-certified clinical neuropsychologist, professor of psychiatry at the University of California San Diego, and director of Neuropsychological Assessment Unit at the VA San Diego Healthcare System. He is recipient of a Mid-Career Investigator Award in Patient-Oriented Research from the National Institute on Aging. His NIH-funded research centers on the cognitive and brain changes of individuals at risk for dementia, and he has published more than 120 articles, books, and book chapters. Dr. Bondi is a Fellow of the American Psychological Association and National Academy of Neuropsychology of the American Psychological Association, and member of the board of directors of the American Board of Clinical Neuropsychology and board of governors of the International Neuropsychological Society. Dr. Bondi maintains a clniical practice in neuropsychology.
Inhaltsangabe
* Chapter 1: Introduction * Chapter 2: Role of Neuropsychological Measurement in MCI and Dementia Assessment * Chapter 3: Normal Cognitive Aging * Chapter 4: Mild Cognitive Impairment * Chapter 5: Alzheimer's Disease * Chapter 6: Vascular Dementia * Chapter 7: Dementia with Lewy Bodies (With Guest Author Tanis J Ferman, PhD) * Chapter 8: Frontotemporal Dementias * Chapter 9: Atypical Dementias (With David P. Salmon, Ph.D.) * Chapter 10: Interventions for the Behavioral Disturbances of Dementia
